Study title: Assessment of the therapeutic efficacy and safety of mizolastine in the treatment of chronic idiopathic urticaria. Open-label study of increasing doses (5-10-20mg per day in 2 divided doses) (URTIOC study). -Sayag J. Tudor D. Demontrond V. Narbonne G. Ben-soussen P.- 05/05/1993
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Immune System Diseases [C20] | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report, Please see report | |||||
| Assessment: | |||||
| Active substance: MIZOLASTINE | |||||
| ATC code: | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: M.34.02.92.005 | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | - | - | |